bioAffinity Technologies, Inc. (BIAF) vs Moleculin Biotech, Inc. (MBRX)
A side-by-side comparison of bioAffinity Technologies, Inc. and Moleculin Biotech, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BIAF
bioAffinity Technologies, Inc.
$6.06HealthcareDelayed quote: Oct 6, 2026, 12:53 PM EDT
MBRX
Moleculin Biotech, Inc.
$0.46HealthcareDelayed quote: Oct 6, 2026, 12:49 PM EDT
Total return — BIAF vs MBRX
growth of $100 · dividends reinvested · last 4yBIAF -99.8% (-79.8%/yr)MBRX -99.9% (-82.9%/yr)BIAF compounded faster over this window
BIAF MBRX
BIAF vs MBRX: by the numbers
- •BIAF is the larger company ($3M vs $2M market cap).
- •Both run net losses; MBRX's is the smaller (0.00% vs -257.33% net margin).
Metrics side by side
Valuation
| Metric | BIAF | MBRX |
|---|---|---|
| P/S ratio | 0.43 | N/A |
| P/B ratio | 0.67 | 0.21 |
Profitability
| Metric | BIAF | MBRX |
|---|---|---|
| Gross margin | 23.21% | 0.00% |
| Operating margin | -171.58% | 0.00% |
| Net margin | -257.33% | 0.00% |
| ROE | -402.92% | -261.73% |
| ROIC | -237.93% | -242.25% |
Growth (annualized)
| Metric | BIAF | MBRX |
|---|---|---|
| Total return CAGR (5Y) | N/A | -78.48% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.